XTANDI Drug Patent Profile

Which patents cover Xtandi, and what generic alternatives are available?

Xtandi is a drug marketed by Astellas and is included in two NDAs. There are seven patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in thirty-six countries.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the enzalutamide profile page.

DrugPatentWatch^® Generic Entry Outlook for Xtandi

Xtandi was eligible for patent challenges on August 31, 2016.

There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are three tentative approvals for the generic drug (enzalutamide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for XTANDI

International Patents:	192
US Patents:	7
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	155
Patent Applications:	4,808
Drug Prices:	Drug price information for XTANDI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XTANDI
What excipients (inactive ingredients) are in XTANDI?	XTANDI excipients list
DailyMed Link:	XTANDI at DailyMed

See drug prices for XTANDI

Recent Clinical Trials for XTANDI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme LLC	Phase 3
Orion Corporation, Orion Pharma	Phase 3
Prostate Cancer Foundation	Phase 1/Phase 2

See all XTANDI clinical trials

Pharmacology for XTANDI

Drug Class	Androgen Receptor Inhibitor
Mechanism of Action	Androgen Receptor Antagonists Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers

Paragraph IV (Patent) Challenges for XTANDI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XTANDI	Tablets	enzalutamide	120 mg and 160 mg	213674	1	2024-12-27
XTANDI	Tablets	enzalutamide	40 mg and 80 mg	213674	1	2021-03-31
XTANDI	Capsules	enzalutamide	40 mg	203415	3	2016-08-31

US Patents and Regulatory Information for XTANDI

XTANDI is protected by twenty-one US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes	12,502,357
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes	7,709,517		Y	Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020		RX	Yes	No	7,709,517		Y	Y
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes	8,183,274
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes	12,447,128
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes	12,161,628

EU/EMA Drug Approvals for XTANDI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Xtandi	enzalutamide	EMEA/H/C/002639Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.	Authorised	no	no	no	2013-06-21	2013-04-26

International Patents for XTANDI

When does loss-of-exclusivity occur for XTANDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Israel

Russian Federation

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XTANDI around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20230003445	디아릴히단토인 화합물 (DIARYLHYDANTOIN COMPOUNDS)
South Africa	201201793	DIARYLHYDANTOIN COMPOUNDS
Denmark	2444085
Mexico	2021000007
Mexico	2007014132	COMPUESTOS DE DIARILHIDANTOINA. (DIARYLHYDANTOIN COMPOUNDS.)
South Korea	20130060369	DIARYLHYDANTOIN COMPOUNDS
European Patent Office	4169908

Supplementary Protection Certificates for XTANDI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893196	PA2013029	Lithuania		PRODUCT NAME: ENZALUTAMIDUM; REGISTRATION NO/DATE: EU/1/13/846 20130621
1893196	92338	Luxembourg		PRODUCT NAME: ENZALUTAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES (XTANDI); FIRST REGISTRATION DATE: 20130625
1893196	CA 2013 00065	Denmark		PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
1893196	13C0071	France		PRODUCT NAME: ENZALUTAMIDE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/846 20130625
1893196	2013/061	Ireland		PRODUCT NAME: ENZALUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/846 20130625
1893196	122013000155	Germany		PRODUCT NAME: ENZALUTAMID ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/13/846 20130621
1893196	SPC/GB13/079	United Kingdom		PRODUCT NAME: ENZLUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/846 20130625

XTANDI (enzalutamide): Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is XTANDI and where does it sit in prostate cancer care?

XTANDI is enzalutamide, an oral androgen receptor (AR) inhibitor used in prostate cancer across multiple stages, including metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) (U.S. FDA label: XTANDI prescribing information). Enzalutamide’s commercial footprint has been driven by (1) label expansion over time, (2) continued uptake in high-acuity metastatic settings, and (3) competitive positioning versus other AR-targeted agents and chemotherapy.

How has XTANDI’s market expanded and what is the demand engine?

XTANDI’s demand engine is label breadth across metastatic disease states where AR pathway inhibition remains a core treatment line. Commercially, that translates to sustained addressable patient populations in prostate cancer with repeated opportunities to secure placement across treatment sequencing and geographic reimbursement decisions (FDA label; company reporting through filings).

Key market dynamics:

• Long-lived base: Prostate cancer is chronic in many metastatic trajectories, which extends exposure windows for established agents.
• Line-of-therapy penetration: XTANDI has historically benefited from uptake in earlier and later lines as clinical evidence matured and prescribing patterns shifted.
• Health system adoption: Uptake follows reimbursement coverage and treatment guideline inclusion, which can lag clinical evidence by quarters to years (FDA label; payer and guideline impact reflected in subsequent quarterly performance in company reporting).

What are the core competitive pressures affecting XTANDI revenue?

XTANDI operates in a crowded AR-targeted landscape. The main competitive pressures are:

• Other AR pathway inhibitors: Agents in the same therapeutic class compete on efficacy in specific subgroups, toxicity profile, co-administered sequencing, and prescriber preference (reflected in net sales trends across the class in company reporting).
• Chemotherapy and combination standards: Treatment standards in metastatic disease evolve, which can shift utilization away from any single AR agent when guidelines favor different combinations.
• Geographic and reimbursement variability: Pricing and access differences across the US, EU5, and rest-of-world can create lumpy performance.

How has XTANDI’s financial trajectory looked in the public domain?

XTANDI is marketed by Astellas Pharma and Pfizer via a co-promotion and distribution structure that historically has resulted in Astellas reporting royalty and revenue share dynamics and Pfizer reporting partnership-driven results (company filings and annual reporting). The financial trajectory for XTANDI has been characterized by:

• Multi-year revenue scale supported by label expansion and durable utilization.
• Mid-cycle volatility driven by competition, price pressure, and sequence shifts.
• Ongoing adjustments from geographic mix and payer controls.

The public record confirms continued commercial presence and ongoing regulatory labeling under the XTANDI brand (FDA label).

What does the latest regulatory and safety labeling imply for commercialization risk?

XTANDI’s FDA labeling defines the boundaries for use and is a direct constraint on addressable markets. Commercial implications flow from:

• Indication-specific eligibility: Uptake depends on meeting the label’s disease-state criteria (FDA label).
• Safety and monitoring requirements: The label’s warnings and dose considerations drive prescribing behavior and adherence, affecting real-world persistence (FDA label).
• Formulation and administration: The label’s dosing and administration rules influence switching and patient selection (FDA label).

What are the commercialization tailwinds and drag factors?

Tailwinds:

• Evidence-backed placement in metastatic disease supports continued prescribing across multiple cohorts within prostate cancer care pathways (FDA label).
• Oral administration supports persistence and convenience compared with many IV-based regimens (FDA label).

Drag factors:

• Class competition pressures market share and net pricing.
• Evolving sequencing can shift patients away from enzalutamide to other agents if incremental outcomes or toxicity/treatment burden favor competitors.
• Payer scrutiny: Cost-effectiveness assessments and formulary decisions can curb adoption even when clinical benefit exists.

How do partnership economics and reporting structure affect what investors see?

XTANDI financials are not a single “company revenue line” in most investor views due to the commercial structure. Public disclosures often split value between:

• Partner-reported sales vs. royalties and profit-share mechanics
• Territory rights differences
• Commercial collaboration accounting

This matters for interpretation: a quarter with soft market demand in total prescriptions can still show different reported revenue outcomes depending on how each company accounts for distribution and royalties (company reporting via filings).

Market mapping: what segments drive XTANDI revenue most directly?

From a market-dynamics lens, the revenue base is driven by:

• mCRPC: where AR inhibition is a standard pillar and where competitive take rates determine net revenue.
• mHSPC: where earlier adoption can expand the addressable population and improve lifetime value per patient, assuming reimbursement and guideline uptake.

The FDA label provides the clinical boundaries that define these segments (FDA label).

Financial trajectory indicators to track going forward

For a live view of XTANDI’s trajectory, the key observable indicators are:

1. Prescription and utilization trends in metastatic prostate cancer in the US and major EU markets (proxy metrics via sales disclosures and class trends in filings).
2. Net sales vs. growth rate (slowing or re-acceleration indicates mix shift, pricing changes, or share movement).
3. Geographic mix: higher growth regions can mask flat demand in core markets.
4. Formulary status changes: payer changes can cause step-function impacts.

These indicators are the practical way to connect market dynamics to the financial curve investors ultimately price.

Key Takeaways

• XTANDI is an AR-targeted anchor in metastatic prostate cancer, with commercialization tied to label breadth and uptake across mCRPC and mHSPC settings (FDA label).
• Revenue trajectory reflects not only clinical adoption but also treatment sequencing, payer controls, and competition within AR pathway inhibitors, which can create volatility even with durable demand.
• Reported financial performance depends on partnership economics and accounting structure, so interpreting “sales trajectory” requires mapping market demand to company-specific reporting mechanics (company filings through reporting).
• The highest-signal forward metrics are net sales growth rate, geographic mix shifts, and utilization proxies in metastatic prostate cancer, since these most directly translate market dynamics into cash flow outcomes.

---

FAQs

1) Is XTANDI used in metastatic hormone-sensitive prostate cancer?

Yes. XTANDI has indications that include metastatic hormone-sensitive prostate cancer within the scope of its FDA-approved labeling (XTANDI prescribing information).

2) What is the drug’s mechanism of action that drives its market fit?

XTANDI (enzalutamide) is an androgen receptor inhibitor, blocking AR signaling pathways that drive prostate cancer growth (FDA label).

3) What are the main competitive risks to XTANDI revenue?

Competitive risks come from other AR-targeted agents and shifts in treatment sequencing as standards evolve (FDA label and class market dynamics reflected in continued competitive landscape in oncology).

4) How do partnership economics influence how investors view XTANDI results?

Because XTANDI commercialization involves multiple parties and territory arrangements, companies may report value as partner sales, royalties, or profit share rather than a simple standalone drug revenue line (company reporting).

5) What labeling elements matter most for commercial access?

Indication eligibility and safety requirements in the FDA label matter because they define patient eligibility, monitoring requirements, and prescribing constraints (FDA label).

---

References

[1] U.S. Food and Drug Administration. (2024). XTANDI (enzalutamide) prescribing information. FDA. https://www.accessdata.fda.gov/